We’re going to Madrid! Meet ONCOassist at ESMO 2026

We’re going to Madrid! Meet ONCOassist at ESMO 2026

We’re thrilled to announce that ONCOassist will be exhibiting at the European Society for Medical Oncology (ESMO) Congress 2026. Join us in Madrid this October and see how we’re transforming clinical decision support for oncology healthcare professionals.

Find us at Hall 10, Booth 1091

How to Find Us on the Exhibition Floor

Enter Hall 10 from the Avenida and head for the back wall of the hall (on your left as you walk in). Follow the row of stands along that wall. ONCOassist is about halfway along, at Booth 1091, between Delcath Systems (1092) and Noah AI (1090).

Note: These directions are based on the ESMO 2026 exhibition floor plan for IFEMA Madrid. Look out for signage on the day, or ask a congress volunteer if you need help finding our booth.

We look forward to seeing you in Madrid! #ESMO26 #ONCOassist

ONCO-IQ Quiz Cup: four days, daily winners, one champion

ONCO-IQ Quiz Cup: four days, daily winners, one champion

No time to read it all? Start with these 10

  1. What it is: A daily clinical knowledge competition run by ONCOassist, across 4 days during the ESMO Congress 2026 in Madrid.
  2. Who can play: Consultants/Attendings, Trainees/Fellows, and Physician Assistants on the ONCOassist platform.
  3. Play from anywhere: No in-person attendance required; open to eligible clinicians worldwide.
  4. How to join: Download the ONCOassist app (iOS/Android) or access the web app, sign in, and open the ONCO-IQ section. Click here to download. 
  5. The format: 5 questions each day on the previous day’s key data, written by the ONCOassist clinical team; a new quiz goes live each morning.
  6. Daily window: Submit between 06:00–20:00 Madrid time, entries outside the window don’t count (clocks change Sun 26 Oct; the window follows local time).
  7. One shot: One submission per account per quiz, final once submitted; multiple accounts mean disqualification.
  8. Scoring: 1 point per correct answer, up to 20 across the four quizzes; ties are broken by fastest total completion time.
  9. Prizes: $100 voucher for each day’s top scorer; overall top 3 win gold/silver/bronze medals plus $200/$100/$50 vouchers, with the champion’s name engraved on the trophy.
  10. Don’t miss a quiz: Turn on app notifications; the Champion is crowned after Quiz 4 on Tuesday 27 October.

 

Got a few minutes? The complete guide

ABOUT THE ONCO-IQ CUP

The ONCO-IQ Cup is a daily clinical knowledge competition running across 4 days during the ESMO Congress 2026 in Madrid. Each quiz is written by the ONCOassist clinical team based on the key practice-changing findings publicly presented at the congress’s oral, late-breaking, and plenary sessions. Top performers each day win prizes, and the participant with the highest cumulative score takes home the ONCO-IQ Cup. The competition is open to eligible participants worldwide; you do not need to attend the congress in person to take part.

 

REGISTRATION & ELIGIBILITY

Q: Who can participate?

The ONCO-IQ Cup is open to Consultants/Attendings, Trainees/Fellows, and Physician Assistants on the ONCOassist platform. The competition is open to eligible participants worldwide; in-person attendance at the congress is not required.

Q: When will the competition be live?

The competition leaderboard and scoring are active only between 06:00 and 20:00 Madrid local time each day. Only submissions made during this time period count toward the competition. The quiz can still be accessed and completed at other times after it is released; however, submissions made outside the competition window will not be counted toward the competition.

Q: How do I register to play?

You must have an active ONCOassist app account to participate. If you are not yet registered, download the ONCOassist mobile app (iOS/Android) or webapp, create your account, and navigate to the ONCO-IQ section to join the competition. Participation is limited to Consultants/Attendings, Trainees/Fellows, and Physician Assistants.

Q: Can I enter the quiz multiple times?

No. Each ONCOassist account is permitted one submission per daily quiz. Once you submit your answers, that entry is final and cannot be retaken.

Q: Can I create multiple accounts to play more than once?

No. Multiple accounts per individual are not permitted and will result in disqualification. Any duplicate or fraudulent accounts identified will be removed, and all associated entries voided.

 

QUIZ SCHEDULE

Each quiz covers data from the previous day’s sessions and goes live the following morning. Each quiz has the same five-question format.

ONCOquiz Table

The overall ONCO-IQ Cup Champion is crowned after Quiz 4 closes on Tuesday 27 October.

All times are Madrid local time. Note that clocks in Madrid move back one hour in the early hours of Sunday 26 October (CEST → CET); the daily 06:00–20:00 window always follows the local clock.

SCORING & HOW THE WINNER IS DETERMINED

Q: How is each quiz scored?

Each correctly answered question earns one point. Your score for each daily quiz is the total number of correct answers. All daily scores are summed to produce your cumulative ONCO-IQ Cup total (maximum 20 points overall; maximum 5 points per quiz).

Q: How is the overall ONCO-IQ Cup winner determined?

The participant with the highest cumulative score across all four daily quizzes is crowned the ONCO-IQ Cup Champion. Please note that there are two leaderboards: a validated and a non-validated leaderboard. As validation is not mandatory in some countries, ONCOassist will review and combine results from both leaderboards to determine the overall winner.

Q: What happens if two or more participants have the same total score?

In the event of a tie, the tiebreaker is the total combined time taken to complete all submitted quizzes; the participant who completed the quizzes in the shortest total time across all days is declared the winner. If a tie persists after the time tiebreaker, the organizing team will determine the winner at their discretion and notify the relevant participants directly.

Q: Is there a daily leaderboard?

Yes. A live ONCO-IQ leaderboard is updated within the ONCOassist app after each daily quiz closes, so you can track your ranking throughout the congress.

PRIZES & RECOGNITION

Overall prizes

🥇 1st place: Name engraved on the official ONCO-IQ Cup trophy*, a gold medal, a $200 Amazon voucher, and recognition across ONCOassist channels (in-app, newsletter, social media).

🥈 2nd place: A silver medal, a $100 Amazon voucher, and recognition across ONCOassist channels.

🥉 3rd place: A bronze medal, a $50 Amazon voucher, and recognition across ONCOassist channels.

*The trophy is retained by ONCOassist.

Daily prize (awarded each day)

1st place each day: A $100 Amazon voucher, plus recognition via in-app announcement, social media, and our daily newsletter.

Q: Are there prizes for daily performance?

Yes. The top daily quiz winner each day receives a $100 Amazon voucher and is recognized with an in-app announcement, social media recognition, and a mention in our daily newsletter. The top 3 daily finishers receive recognition on our social media and in the daily newsletter. Daily prizes are finalized at the end of each day (Madrid local time) and are awarded independently of the overall Cup standings.

Q: Can I win a daily prize and the overall Cup?

Absolutely. Daily prizes and the overall trophy are separate awards; the same participant can win both.

Q: How will prize winners be notified?

Daily prize winners are notified via email and announced through our social media channels. The overall Cup winner is contacted directly through their registered ONCOassist account details and recognized across our social media channels.

Q: How does the trophy work for a global competition?

The ONCO-IQ Cup trophy is retained by ONCOassist. The overall winner’s name is engraved on the trophy after the competition concludes, and a photo of the winner with the engraved trophy will be taken at the next major congress (where possible). The winner also receives a gold medal.

GENERAL QUESTIONS

Q: What topics do the quizzes cover?

Each quiz is written by the ONCOassist clinical team from the key data publicly presented at the congress, spanning lung cancer, breast cancer, GI cancers, genitourinary cancers, melanoma, sarcoma, targeted therapy, and more. Each daily quiz contains 5 questions covering the highlights of the previous day’s sessions.

Q: Do I need to attend the congress in person to participate?

No. The ONCO-IQ Cup is open to eligible clinicians worldwide. You do not need to be present in Madrid to compete. Quizzes are based on data publicly presented at the congress and are accessible through the ONCOassist app from anywhere. Make sure to complete the quiz within the 06:00–20:00 Madrid-time window each day to be counted in the competition.

Q: What if I miss a day’s quiz or submit my answers after the window closes?

Each daily quiz has a fixed submission window. If you miss a quiz, you receive a score of zero for that day. We recommend enabling notifications in the ONCOassist app and setting a reminder so you don’t miss when a quiz goes live or when the submission window closes.

Q: Who do I contact if I have a problem?

Please contact the ONCOassist support team through the in-app help function, or by emailing kevin@portablemedicaltechnology.com or eoin@portablemedicaltechnology.com.

If you’re attending in person, visit ONCOassist at Booth 1091.

The ONCO-IQ Cup is an independent ONCOassist competition. It is not affiliated with, endorsed by, or an official event of ESMO. Participation and prizes are subject to eligibility and any applicable local rules.

We’re Going to Chicago! Meet ONCOassist at ASCO 2026

We’re Going to Chicago! Meet ONCOassist at ASCO 2026

We’re thrilled to announce that ONCOassist will have its first-ever booth at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. Join us in Chicago this May/June and see how we’re transforming clinical decision support for oncology healthcare professionals.

How to Find Us on the Exhibition Floor

Navigate from the Grand Concourse entrance and head up the main aisle between the ASCO and Merck booths. Continue until you reach EMD Serrano and Johnson and Johnson stand. Turn left at that point and follow the corridor to the end. ONCOassist is on your right- hand side, just past the Regeneron stand.

Note: These directions are specific to the exhibition layout at McCormick Place, Chicago. Look out for signage on the day, or ask a conference volunteer if you need assistance finding our booth. 

We look forward to seeing you in Chicago. #ASCO26 #ONCOassist

ONCOassist Launches ONCO-IQ: A Quiz-Based Learning Feature Bringing Interactivity to Oncology Education

ONCOassist Launches ONCO-IQ: A Quiz-Based Learning Feature Bringing Interactivity to Oncology Education

Killarney, Ireland – 10 November 2025 – ONCOassist®, the world’s leading oncology decision-support platform used by more than 100,000 oncology professionals across 180 countries, has announced the launch of ONCO-IQ, a new quiz-based learning feature that turns oncology education into an engaging, evidence-driven experience.

Designed specifically for oncologists, ONCO-IQ presents short, focused clinical quizzes covering the latest trial data, treatment updates, and evolving standards of care. Each quiz allows users to test their knowledge, view evidence-based explanations, and compare results with peers around the world—all within the trusted ONCOassist environment.

“With ONCO-IQ, we wanted to make learning in oncology more interactive, practical, and enjoyable,” said Eoin O’Carroll, CEO and Co-Founder of ONCOassist. “Clinicians are constantly faced with new data and changing guidelines. By transforming this information into concise, quiz-style challenges, we help oncology professionals stay sharp, confident, and informed—without adding to their workload.”

Kevin Bambury, Co-Founder and Chief Commercial Officer of ONCOassist, added:

“Pharma and medical education partners are increasingly looking for compliant, measurable ways to reach oncology professionals. ONCO-IQ delivers a science-driven, gamified format that encourages real engagement—allowing partners to support education and awareness initiatives while providing actionable analytics on knowledge uptake.”

Dr. Richard Bambury, Chief Medical Officer at ONCOassist, commented:

“As an oncologist, I know how valuable it is to test knowledge in real time. ONCO-IQ brings that opportunity directly into the clinician’s workflow—quick, evidence-based quizzes that reinforce understanding of the latest advances in cancer care. It’s an innovative way to support continuous learning while keeping the focus on patient outcomes.”

Built on ONCOassist’s CE-approved, evidence-based platform, ONCO-IQ offers a compliant, high-impact channel for pharmaceutical and medical-education partners to collaborate on oncology knowledge-reinforcement initiatives. Every quiz undergoes medical review to ensure scientific accuracy, educational integrity, and fair balance.

ONCO-IQ is now available to verified oncologists and physicians in the U.S. through the ONCOassist app and web platform. Access for oncology nurses and allied health professionals is planned for 2026.

About ONCOassist®

ONCOassist is a CE-approved clinical decision-support platform created by Portable Medical Technology Ltd. It provides oncology healthcare professionals with validated calculators, prognostic tools, toxicity management guidelines, staging criteria, and educational resources in one easy-to-use platform. ONCOassist partners with pharmaceutical companies, medical societies, and research organizations to advance oncology education and improve clinical decision-making globally.

Media Contact:
ONCOassist® – Media Relations 📧 eoin@portablemedicaltechnology.com
🌐 www.oncoassist.com

Weekly Oncology Highlights | Oncology News, Updates and Spotlights

Screenshot 2025 07 25 at 1.32.03 PM

Your go-to digest for the latest breakthroughs in cancer care.

This week’s digest spans across FDA approvals and NCCN guideline updates. 

Scroll down to read more on this week’s ONCOassist Spotlight Tool ! 

FLAME Trial: 10-Year Focal-Boost Radiotherapy Results in Prostate Cancer

The FLAME Phase III trial confirms that a focal boost (up to 95 Gy) to MRI-visible intraprostatic lesions alongside standard EBRT significantly increases 10-year biochemical disease-free survival (86% vs. 71%) in intermediate- to high-risk localized prostate cancer, without additional toxicity. Other disease-free metrics also favored the boost arm.
(Ref: Menne Guricová, K.et al (2025). Focal boost to the intraprostatic tumor in external beam radiotherapy for localized prostate cancer: 10-year outcomes of the FLAME trial. Journal of Clinical Oncology, Advance online publication.)

Click here for more

Modeyso (Dordaviprone): First FDA-Approved Systemic Therapy for H3 K27M-Mutant DMG

The FDA granted accelerated approval to Modeyso (dordaviprone) for both adult and pediatric patients (≥1 year) with recurrent H3 K27M-mutant diffuse midline glioma. This marks the first systemic therapy approved for this aggressive brain tumor subtype. Clinical data show an objective response rate of approximately 22%, with a median duration of response of ~10.3 months.
(Ref:Jazz Pharmaceuticals. (2025, August 6). FDA grants accelerated approval to dordaviprone (Modeyso) for H3 K27M-mutant diffuse midline glioma [Press release].)

Click here for more

Enhertu (T-DXd) Approved for HER2-Low and HER2-Ultralow Metastatic Breast Cancer

The FDA expanded approval of fam-trastuzumab deruxtecan-nxki (Enhertu) for hormone receptor–positive metastatic breast cancer expressing HER2-low (IHC 1+/2+, ISH−) or HER2-ultralow (IHC 0 with minimal staining), post-endocrine therapy. This extends targeted ADC treatment to previously underserved patient subsets.
(Ref: U.S. Food and Drug Administration. (2025, January 27). FDA approves fam-trastuzumab deruxtecan-nxki for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer [Press release].)

Click here for more

NCCN Guidelines Now Include LEMS Evaluation in SCLC Care Pathways

The updated NCCN Clinical Practice Guidelines for Small Cell Lung Cancer now recommend evaluation for Lambert-Eaton Myasthenic Syndrome (LEMS), including neurologic consultation, PQ- and N-type VGCC antibody testing, and consideration of amifampridine for symptomatic management.
(Ref: Catalyst Pharmaceuticals. (2025, August 6). LEMS antibody testing and treatment recommendations added to NCCN guidelines for SCLC [Press release].)

Click here for more

Bacterial Decolonization with Mupirocin Ointment Reduces Severe AROM in NPC Radiotherapy

A Phase III randomized clinical trial in nasopharyngeal carcinoma patients undergoing definitive chemoradiotherapy compared a bacterial decolonization (BD) protocol using mupirocin nasal ointment with standard of care (SoC). The BD regimen significantly halved the rate of severe (grade ≥3) acute radiation oral mucositis (AROM)—from 47.7% to 22.7% (relative risk 0.48; P < .001). Secondary benefits included reduced oral pain, eased swallowing difficulty, and lower rates of nasal and oral Staphylococcus aureus colonization. Results suggest that mupirocin decolonization is a promising, cost-effective approach for alleviating AROM in nasopharyngeal cancer patients undergoing radiotherapy
(Ref: Liao, Z., Xiong, X., Zhao, L., et al. (2025). Bacterial decolonization with mupirocin ointment for acute radiation oral mucositis prevention: A Phase III randomized clinical trial. JAMA Oncology. Advance online publication.)

Click here for more

ONCOassist Tool Spotlight: Metastatic Castrate Resistant Prostate Cancer Tool

Systemic treatment options for mCRPC include:For Reference 320 x 250 px 2000 x 2000 px 1

  • AR pathway inhibitors (ARPi)
  • Cytotoxic chemotherapy
  • Radioligand therapy
  • PARP inhibitors and others.

This tool is designed to show efficacy outcomes with novel treatment options in recent clinical trials for mCRPC patient.

Join the ONCOassist oncology community, the go-to CE‑approved app for oncology professionals worldwide !

Screenshot 2025 06 25 at 2.39.33 PM

  •  Access essential tools like staging systems, toxicity scoring, drug calculators, prognostic scores and NCCN regimens,all in one place .
  • Stay informed with ONCOnews & ONCOvideos featuring expert insights, conference coverage and peer-tested protocols 

Download the app here:

📱IOS                                  📱Android                              💻 Webapp

 

Weekly Oncology Highlights | Oncology News, Updates and Spotlights

Screenshot 2025 07 25 at 1.32.03 PM

Your go-to digest for the latest breakthroughs in cancer care.

This week’s digest spans EU approvals in myeloma and lung cancer, precision-driven trials in breast and hematologic oncology, and a biomarker breakthrough in lung adenocarcinoma brain metastasis.

Leading voices. Big insights. Scroll down for Dr. Maria Barbu!

 

Sarclisa (Isatuximab) Gains EU Approval in Transplant-Eligible Newly Diagnosed Multiple Myeloma

On July 25, 2025, the European Commission approved Sarclisa combined with VRd (bortezomib, lenalidomide, dexamethasone) as induction therapy for transplant-eligible NDMM. The GMMG-HD7 Phase III trial showed significant MRD negativity and prolonged progression-free survival versus VRd alone.
Clinical insight: This approval broadens Sarclisa’s role to include early disease lines, regardless of transplant eligibility.
(Ref: Sanofi press release citing GMMG-HD7 results and EC approval, July 25, 2025)

View more

CHMP Recommends TEVIMBRA (Tislelizumab) for Resectable NSCLC (RATIONALE-315) Trial

On July 28, 2025, CHMP issued a positive opinion for TEVIMBRA plus platinum-based chemo as neoadjuvant therapy followed by adjuvant monotherapy in high-risk resectable NSCLC. In the Phase III RATIONALE‑315 trial, TEVIMBRA significantly improved MPR (56.2% vs 15.0%), pCR (40.7% vs 5.7%), and event-free survival (HR 0.56; P=0.0003).
Practice relevance: Could establish the first perioperative immunotherapy standard in early-stage NSCLC.
(Ref: BeOne Medicines CHMP recommendation release, July 28, 2025)

View more

TEODOR Trial Launched to Evaluate ct-DNA Guided  De-escalation in HR+ Breast Cancer

Natera and ABCSG have initiated the TEODOR Phase II RCT, investigating whether hormone receptor-positive, HER2-negative patients who are ctDNA-negative and endocrine-responsive can safely skip neoadjuvant chemotherapy in favor of endocrine therapy. Primary endpoints are pCR rate and modified PEPI score.
Innovative approach: Personalizes neoadjuvant decision-making via ctDNA and endocrine sensitivity metrics.
(Ref: Natera press release announcing TEODOR trial launch, July 29, 2025)

View more

Pirtobrutinib (Jaypirca) Meets Primary Endpoint Against Ibrutinib in First-Line CLL/SLL (BRUIN CLL-314)

On July 29, 2025, Lilly announced that pirtobrutinib demonstrated non-inferiority and statistical superiority, in overall response rate versus ibrutinib in treatment-naïve or BTKi-naïve CLL/SLL, in the head-to-head BRUIN CLL‑314 Phase III trial. PFS data is immature but trending favourably.
Clinical takeaway: This is first head-to-head evidence supporting a non-covalent BTK inhibitor in frontline CLL/SLL.
(Ref: Lilly press release with BRUIN trial topline results, July 29, 2025)

View more

Neuronatin (NNAT) Overexpression Predicts Brain Metastatis and Poor Survival in Lung Adenocarcinoma

A retrospective study of 200 lung adenocarcinoma patients (33 with brain metastasis) showed that nuclear NNAT immunopositivity corresponded with significantly shorter overall survival (7.6 vs 24.4 months) and independently predicted brain metastasis risk. NNAT-IRS positivity was similarly linked to diminished outcomes.
Translational insight: NNAT may serve as a valuable early prognostic biomarker to stratify high-risk patients for brain-directed surveillance and intervention.
(Ref: Basaran Goksen et al. Scientific Reports 2025;15:27653)

View more

This week’s Oncology Spotlight: Dr. Maria Barbu on Cancer Care in Romania!

In this week’s special segment from IUCS 2024, we speak with Dr. Maria Barbu, a medical oncologist from Bucharest, Romania. CLICK HERE TO WATCH!Oncology Spotlight 45 1Dr. Barbu shares her perspective on the evolving oncology landscape in Eastern Europe, particularly in the treatment of prostate cancer.Explore more stories & insights on ONCOassist. Your clinical edge, just a tap away. 

Join the ONCOassist oncology community, the go-to CE‑approved app for oncology professionals worldwide !

Screenshot 2025 06 25 at 2.39.33 PM

  •  Access essential tools like staging systems, toxicity scoring, drug calculators, prognostic scores and NCCN regimens,all in one place .
  • Stay informed with ONCOnews & ONCOvideos featuring expert insights, conference coverage and peer-tested protocols 

Download the app here:

📱IOS                                  📱Android                              💻 Webapp